表紙
市場調查報告書

老年性黃斑部病變(AMD):開發中產品分析

Age Related Macular Degeneration - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 213105
出版日期 內容資訊 英文 753 Pages
訂單完成後即時交付
價格
Back to Top
老年性黃斑部病變(AMD):開發中產品分析 Age Related Macular Degeneration - Pipeline Review, H2 2019
出版日期: 2019年12月27日內容資訊: 英文 753 Pages
簡介

所謂老年性黃斑部病變(AMD)是五十歲以上老人最常見的失明原因。是由於黃斑部病變造成視線扭曲、朦朧。容易罹病的危險因子有年齡、吸煙、日光、遺傳等。主要的症狀有盲點、視線模糊等。主要的治療方法有光線力學療法、放射線療法、藥物療法(抗血管新生藥等)。維他命和改善飲食習慣也證實有效。

本報告提供老年性黃斑部病變 (AMD) 的治療藥開發情形調查分析,提供您開發中產品概要,臨床實驗的各階段產品概要,主要企業簡介,藥物簡介,開發中產品的最新趨勢,最新消息和新聞稿等相關的系統性資訊。

簡介

老年性黃斑部病變 (AMD)的概要

治療藥的開發

老年性黃斑部病變 (AMD) :企業開發中的治療藥

老年性黃斑部病變 (AMD) :大學/機關研究中的治療藥

老年性黃斑部病變 (AMD) :開發中產品概況

老年性黃斑部病變 (AMD) :企業開發中的產品

老年性黃斑部病變 (AMD) :大學/機關研究中的產品

老年性黃斑部病變 (AMD)的治療藥的開發企業

老年性黃斑部病變 (AMD) :治療藥的評估

藥物簡介

老年性黃斑部病變 (AMD) :最近的開發平台趨勢

老年性黃斑部病變 (AMD) :暫停中的計劃

老年性黃斑部病變 (AMD) :開發中止的產品

老年性黃斑部病變 (AMD) :產品開發的里程碑

附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11786IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Age Related Macular Degeneration - Pipeline Review, H2 2019, provides an overview of the Age Related Macular Degeneration (Ophthalmology) pipeline landscape.

Age related macular degeneration is the most common reason for vision loss in people aged above 50. It results in depreciation of the macula that may lead to distorted or blurry central vision. The predisposing factors involved are age, smoking, sunlight, heredity etc. Symptoms include development of blind spot and hazy vision. The condition may be treated by photodynamic therapy, radiation therapy and medication such as anti-angiogenic drugs.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Age Related Macular Degeneration - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Age Related Macular Degeneration (Ophthalmology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Age Related Macular Degeneration (Ophthalmology) pipeline guide also reviews of key players involved in therapeutic development for Age Related Macular Degeneration and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 15, 32, 32, 3, 154, 31 and 3 respectively. Similarly, the Universities portfolio in Phase I, Preclinical and Discovery stages comprises 1, 16 and 1 molecules, respectively.

Age Related Macular Degeneration (Ophthalmology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Age Related Macular Degeneration (Ophthalmology).
  • The pipeline guide reviews pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Age Related Macular Degeneration (Ophthalmology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Age Related Macular Degeneration (Ophthalmology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Age Related Macular Degeneration (Ophthalmology)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Age Related Macular Degeneration (Ophthalmology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Age Related Macular Degeneration (Ophthalmology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Introduction
  • Age Related Macular Degeneration - Overview
  • Age Related Macular Degeneration - Therapeutics Development
  • Age Related Macular Degeneration - Therapeutics Assessment
  • Age Related Macular Degeneration - Companies Involved in Therapeutics Development
  • Age Related Macular Degeneration - Drug Profiles
  • Age Related Macular Degeneration - Dormant Projects
  • Age Related Macular Degeneration - Discontinued Products
  • Age Related Macular Degeneration - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Age Related Macular Degeneration, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Products under Development by Companies, H2 2019
  • Products under Development by Companies, H2 2019 (Contd..1), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..2), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..3), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..4), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..5), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..6), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..7), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..8), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..9), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..10), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..11), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..12), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..13), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..14), H2 2019
  • Products under Development by Companies, H2 2019 (Contd..15), H2 2019
  • Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Stage and Target, H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..2), H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..3), H2 2019
  • Number of Products by Stage and Target, H2 2019 (Contd..4), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..1), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..2), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..3), H2 2019
  • Number of Products by Stage and Mechanism of Action, H2 2019 (Contd..4), H2 2019
  • Number of Products by Stage and Route of Administration, H2 2019
  • Number of Products by Stage and Molecule Type, H2 2019
  • Age Related Macular Degeneration - Pipeline by 3SBio Inc, H2 2019
  • Age Related Macular Degeneration - Pipeline by 4D Molecular Therapeutics Inc, H2 2019
  • Age Related Macular Degeneration - Pipeline by Abpro Corp, H2 2019
  • Age Related Macular Degeneration - Pipeline by Abzyme Therapeutics LLC, H2 2019
  • Age Related Macular Degeneration - Pipeline by Achillion Pharmaceuticals Inc, H2 2019
  • Age Related Macular Degeneration - Pipeline by Acucela Inc, H2 2019
  • Age Related Macular Degeneration - Pipeline by AdAlta Ltd, H2 2019
  • Age Related Macular Degeneration - Pipeline by Adverum Biotechnologies Inc, H2 2019
  • Age Related Macular Degeneration - Pipeline by Aerie Pharmaceuticals Inc, H2 2019

List of Figures

  • Number of Products under Development for Age Related Macular Degeneration, H2 2019
  • Number of Products under Development by Companies, H2 2019
  • Number of Products under Development by Universities/Institutes, H2 2019
  • Number of Products by Top 10 Targets, H2 2019
  • Number of Products by Stage and Top 10 Targets, H2 2019
  • Number of Products by Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Stage and Top 10 Mechanism of Actions, H2 2019
  • Number of Products by Top 10 Routes of Administration, H2 2019
  • Number of Products by Stage and Top 10 Routes of Administration, H2 2019
  • Number of Products by Top 10 Molecule Types, H2 2019
  • Number of Products by Stage and Top 10 Molecule Types, H2 2019
Back to Top